Mathematical models for the effect of anti-vascular endothelial growth factor on visual acuity

The standard of care treatment for neovascular age-related macular degeneration, delivered as ocular injection, is based on anti-vascular endothelial growth factor (anti-VEGF). The course of treatment may need to be modified quickly for certain patients based on their response. Models that track bot...

Full description

Saved in:
Bibliographic Details
Published in:Journal of mathematical biology 2020-12, Vol.81 (6-7), p.1397-1428
Main Authors: Edwards, David A., Emerick, Brooks, Kondic, Anna Georgieva, Kiradjiev, Kristian, Raymond, Christopher, Zyskin, Maxim
Format: Article
Language:English
Subjects:
Acuity
Age
Age related diseases
Applications of Mathematics
Exact solutions
Eye diseases
Growth factors
Macular degeneration
Mathematical and Computational Biology
Mathematical models
Mathematics
Mathematics and Statistics
Parameters
Vascular endothelial growth factor
Visual acuity
Visual aspects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The standard of care treatment for neovascular age-related macular degeneration, delivered as ocular injection, is based on anti-vascular endothelial growth factor (anti-VEGF). The course of treatment may need to be modified quickly for certain patients based on their response. Models that track both the concentration and the response to an anti-VEGF treatment are presented. The specific focus is to assess the existence of analytical solutions for the different types of models. Both an ODE-based model and a map-based model illustrate the dependence of the solution on various biological parameters and allow the measurement of patient-specific parameters from experimental data. A PDE-based model incorporates diffusive effects. The results are consistent with observed values, and could provide a framework for practitioners to understand the effect of the therapy on the progression of the disease in both responsive and non-responsive patients.
ISSN:0303-6812
1432-1416
DOI:10.1007/s00285-020-01544-4